NEWS | alsv | Page 2 of 17

Companies in the News

Federation Bio Administers First Dose in Phase 1 Clinical Trial

- Study will assess the safety, efficacy and engraftment of FB-001 for the treatment of enteric hyperoxaluria, a serious metabolic...

Escient Pharmaceuticals Announces $120 Million Series C Financing

Financing led by New Enterprise Associates (NEA), Abingworth and Forge Life Science Partners Proceeds support advancement of EP262 and...

Indigo Expands 2023 Biological Crop Protection Line with New Biofungicide

MEMPHIS, Tenn., Nov. 22, 2022 /PRNewswire/ -- Indigo Agriculture today announced the commercial launch of the industry's first biological...

Neumora Therapeutics Announces $112 Million Series B Financing

Proceeds to support the advancement of Neumora’s mission of building a leading global precision neuroscience company to revolutionize the...

eFFECTOR Therapeutics Doses First Patient in Second Cohort of Phase 1b Clinical Trial of Zotatifin

Dose escalation based on positive recommendation from independent data safety monitoring board after safety review of cohort 1 Drug...

Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of GRANITE

Paper reports that Gritstone’s tumor-specific, neoantigen vaccination approach drives priming and boosting of tumor-specific T cells,...

Gritstone Announces Updated Overall Survival Results in CRC Patients from Phase 1/2 Study of GRANITE

Overall survival (OS) for patients with metastatic, microsatellite stable colorectal cancer (MSS-CRC) who had two prior lines of therapy...

Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform

SOMERVILLE, Mass.--(BUSINESS WIRE)--Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known...

Ansa Biotechnologies Closes Oversubscribed $68 Million Series A Financing

Ansa’s next-generation enzymatic DNA synthesis technology will dramatically accelerate innovation across every industry enabled by...